Lessee, Operating Lease, Liability, Undiscounted Excess Amount of ELITE PHARMACEUTICALS INC /NV/ from 30 Jun 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 30 Jun 2019 to 31 Dec 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Dec 2025 was $262,354, a 42% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $262,354 -$192,193 -42% 31 Dec 2025 10-Q 17 Feb 2026 2026 Q3
Q3 2025 $306,134 -$192,023 -39% 30 Sep 2025 10-Q 14 Nov 2025 2026 Q2
Q2 2025 $352,806 -$201,093 -36% 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q1 2025 $402,300 -$209,818 -34% 31 Mar 2025 10-K 30 Jun 2025 2025 FY
Q4 2024 $454,547 +$453,820 +62424% 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $498,157 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $553,899 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $612,118 +$612,010 31 Mar 2024 10-K 01 Jul 2024 2024 FY
Q4 2023 $727 +$706 31 Dec 2023 10-Q 14 Feb 2024 2024 Q3
Q1 2023 $108* -$156,130 31 Mar 2023 10-Q 14 Aug 2023 2024 Q1
Q4 2022 $21* -$172,286 31 Dec 2022 10-Q 14 Feb 2023 2023 Q3
Q3 2022 $202,000 +$28,403 +16% 30 Sep 2022 10-Q 14 Nov 2022 2023 Q2
Q2 2022 $140,901 30 Jun 2022 10-Q 15 Aug 2022 2023 Q1
Q1 2022 $156,238 31 Mar 2022 10-K 29 Jun 2022 2022 FY
Q4 2021 $172,307 31 Dec 2021 10-Q 14 Feb 2022 2022 Q3
Q3 2021 $173,597 30 Sep 2021 10-Q 15 Nov 2021 2022 Q2
Q2 2020 $175,802 +$134,158 +322% 30 Jun 2020 10-Q 16 Aug 2021 2022 Q1
Q4 2019 $27,214 31 Dec 2019 10-Q 10 Feb 2020 2020 Q3
Q3 2019 $34,072 30 Sep 2019 10-Q 12 Nov 2019 2020 Q2
Q2 2019 $41,644 30 Jun 2019 10-Q 09 Aug 2019 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.